CYCLE-PHARMACEUTICALS
7.9.2020 07:32:08 CEST | Business Wire | Press release
Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, today announced that it has executed a definitive agreement for a $25 million credit facility with Deutsche Bank AG. This strategic financing allows Cycle to build on the success of NITYR® (nitisinone) Tablets , which treats patients with the rare genetic metabolic disease, hereditary tyrosinemia type 1. Cycle’s mission is to utilise the latest pharmaceutical technologies to deliver best-in-class drug treatments to better serve rare genetic disease patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005026/en/
Antonio Benedetti, Chief Executive Officer of Cycle Pharmaceuticals, stated: “Cycle’s agreement with Deutsche Bank provides us with the capital to swiftly and efficiently deliver drug treatments for many genetic rare disease patient groups that urgently need the quality-of-life improvements that the latest pharmaceutical technologies can offer. Cycle also provides individualised patient support services alongside its drug treatments to ensure that a rare disease patient’s needs are met to the greatest extent possible.”
Dimitrios Weedon of Deutsche Bank commented: “This transaction demonstrates Deutsche Bank’s ongoing commitment to supporting innovative and growing businesses. In particular, it exhibits our ability and appetite to provide bespoke financing solutions in the life sciences and biotechnology space. We are delighted to become a key financing partner for Cycle Pharmaceuticals and look forward to working closely with the company in the future.”
Separately, Varsity Pharmaceuticals is incorporated as an independent business, receiving financing from the above transaction. Varsity’s mission is to develop and deliver oncology drug treatments focused on resolving the emerging resistance to PARP inhibitors and other existing drug classes. Varsity uses synthetic lethality approaches and builds on intellectual property developed at the Chemistry Department, University of Cambridge and licensed by Cambridge Enterprise to Varsity. Further pre-clinical work will commence shortly in collaboration with the Cancer Research UK Cambridge Institute, University of Cambridge.
About Cycle Pharmaceuticals
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community. We focus on rare genetic metabolic disorders and neurological conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Mass. (USA). For more information, please visit www.cyclepharma.com and follow us on Twitter , LinkedIn , Facebook and Instagram .
About Cambridge Enterprise
Part of the University of Cambridge, Cambridge Enterprise supports academics, researchers, staff and students in achieving knowledge transfer and research impact. We do this by helping innovators, experts and entrepreneurs use commercial avenues to develop their ideas and expertise for the benefit of society, the economy, themselves and the University.
Liaising with organisations both locally and globally, we offer expert advice and support in commercialisation and social enterprise, including help with academic consultancy services, the protection, development and licensing of ideas, new company and social enterprise creation, and seed funding. For more information, please visit: www.enterprise.cam.ac.uk and follow us on Twitter and LinkedIn .
About The Cancer Research UK Cambridge Institute
The Cancer Research UK Cambridge Institute combines basic and clinical research with innovative technologies to address key questions in the diagnosis and treatment of cancer. As one of the largest cancer research facilities in Europe, we provide an unrivalled biomedical research environment, bringing together the world-class science of the University of Cambridge with clinical and industrial partners at the Cambridge Biomedical Campus. Our research focuses on tumour ecology and evolution, ranging from basic experimental and computational biology through translational cancer research to clinical application. For more information, please visit: www.cruk.cam.ac.uk and follow us on Twitter , LinkedIn , YouTube and Facebook
View source version on businesswire.com: https://www.businesswire.com/news/home/20200906005026/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 09:00:00 CEST | Press release
At Microsoft’s Innovation Hub in Amsterdam, immersive technology is used to enable co-creation rather than one-way presentations. In the company’s Immersive Suite, customers, data experts, and technology specialists come together in a shared environment to address complex challenges more effectively. Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That all
LTM Launches AI 1000 to Develop the Next Generation of Forward Deployed Engineers12.6.2026 08:14:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced AI 1000, a strategic workforce transformation initiative anchored by a dedicated Center of Excellence (CoE). The program will develop a pool of 1,000+ AI-certified engineers, including Forward Deployed Engineers (FDEs), to help enterprises adopt, deploy, and scale AI. The launch comes amid a major shift in enterprise tech talent. The FDE — among the fastest-growing roles in the AI ecosystem — combines the technical knowledge of LLMs and domain SLMs with business understanding to turn ideas into quantifiable ROI accretive outcomes and to drive client adoption. AI 1000 is LTM’s structured response to this shift: it provides the training, platforms, and governed career frameworks to develop FDEs at scale. AI 1000 takes an end-to-end approach to talent development via a four-stage model: Identify, Enable, Deploy, and Govern. It starts by identifying high-potential engineers using a proprietary AI Readi
NTT DATA Group Appoints Kazuhiko Nakayama as New President and Chief Executive Officer12.6.2026 08:00:00 CEST | Press release
Kazuhiko Nakayama appointed President and CEO of NTT DATA Group; Yutaka Sasaki to become Senior Executive Vice President of NTT, Inc. NTT DATA Group, a global leader in AI, digital business and technology services, today announces that the Board of Directors has approved the appointment of Kazuhiko Nakayama as NTT DATA Group’s new President and Chief Executive Officer, effective June 12, 2026. Yutaka Sasaki, former President and CEO of NTT DATA Group, will assume the role of Senior Executive Vice President of NTT, Inc., effective June 18. Serving most recently as CFO of NTT DATA Group, Nakayama brings proven leadership and a depth of expertise and experience in defining business strategy and delivering growth. He will continue to strengthen the competitive advantages of the $30+ billion business whilst accelerating it’s AI-centered growth strategy across the 70+ countries and regions in which it operates. NTT DATA Group’s growth strategy will focus on two key areas alongside its core b
Venture Global Announces Closing of $2.25 Billion of Senior Secured Notes11.6.2026 23:00:00 CEST | Press release
Venture Global LNG, Inc. (“Venture Global”) announced today that its wholly-owned subsidiary, Venture Global LNG, Inc. (the “Issuer”) has closed its offering of $1.125 billion aggregate principal amount of its 6.375% senior secured notes due 2034 (the “2034 Notes”) and $1.125 billion aggregate principal amount of its 6.625% senior secured notes due 2036 (the “2036 Notes” and, together with the 2034 Notes, the “Notes”). The Issuer used the gross proceeds from the offering to redeem all of the Issuer’s outstanding 8.125% senior secured notes due 2028 (the “Existing 2028 Notes”) and used cash on hand to pay the redemption premium and related fees and expenses for the offering and the redemption. The 2034 Notes will mature on December 15, 2034, and the 2036 Notes will mature on June 15, 2036. The Notes were issued at par. The Notes will initially not be guaranteed by any of the Issuer’s subsidiaries. In the future, certain of the Issuer’s subsidiaries that incur or guarantee certain amount
Venture Global and Atlantic-SEE Announce Expansion of Long-Term LNG Sales and Purchase Agreement with Greece11.6.2026 22:30:00 CEST | Press release
Deal doubles quantity of US LNG to be supplied by Venture Global, expanding existing partnership to bolster Central and Eastern European energy securityBuilds on Venture Global’s regasification capacity investment in the Alexandroupolis LNG import terminal to supply U.S. LNG to the region Today, Venture Global, Inc. (NYSE: VG) and ATLANTIC – SEE LNG TRADE S.A. of Greece announced an expansion of their existing Sales and Purchase Agreement (SPA) for the purchase of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. Under the deal, Atlantic-SEE is doubling their existing contract with Venture Global from a minimum of 0.5 million tonnes per annum (MTPA) to 1.0 million tonnes per annum (MTPA). Atlantic-SEE LNG is a newly formed joint venture announced in November at the 6th Partnership for Transatlantic Energy Cooperation (PTEC) conference hosted in Athens, Greece between Greek companies AKTOR Group and DEPA Commercial. The announcement of this expanded
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom